Shanxi Zhendong Pharmaceutical (300158.SZ): has cumulatively repurchased 0.29% of shares.

On February 6, Gelonghui reported that Shanxi Zhendong Pharmaceutical (300158.SZ) announced that as of January 31, 2025, the company has cumulatively repurchased 2,965,600 shares through a dedicated securities repurchase account using centralized bidding methods, accounting for 0.29% of the company's total share capital. The highest Fill Price repurchased was 5.03 yuan per share, the lowest Fill Price was 3.76 yuan per share, and the total amount spent on repurchases was 11.874695 million yuan (excluding trading fees).

Gelonghui FinanceFeb 6 16:57

A-share fluctuation丨Shanxi Zhendong Pharmaceutical fell over 11% due to annual forecast losses + overdue redemption of subsidiary REITs products.

On January 20, Gelonghui reported that Shanxi Zhendong Pharmaceutical (300158.SZ) closed down 11.16% at 3.9 yuan, marking a new low since October of last year, with a total market value falling below 4 billion yuan. The company announced last Friday evening that it expects a Net income loss of 1.15 billion to -1.35 billion yuan attributable to shareholders of the listed company for 2024, compared to a loss of 43.9841 million yuan in the same period last year, with losses continuing to widen year-on-year. In addition, a subsidiary's purchase of a 0.25 billion yuan REITs product has defaulted.

Gelonghui FinanceJan 20 11:32

Express News | Shanxi Zhendong Pharmaceutical: The REITs product purchased by the subsidiary in the amount of 0.25 billion yuan is overdue for repayment.

BreakingsJan 17 20:50

Express News | Shanxi Zhendong Pharmaceutical: It is expected to incur a loss of 1.15 billion to -1.35 billion yuan in 2024.

BreakingsJan 17 20:48

Zhendong Pharmaceutical: 2024 Annual Results Forecast

SZSIJan 17 20:46 · Announcements

The seasonal influenza A has entered the epidemic period, and the sales of related Chinese Patent Medicine products have significantly increased.

① Recently, the positive rate of influenza virus has significantly increased, with over 99% being type A influenza. Market data shows a clear increase in the demand for various Traditional Chinese Medicine cold medicine products. ② Today, stock prices of several listed companies in the Traditional Chinese Medicine Industry, such as Shanxi Zhendong Pharmaceutical, Hainan Huluwa Pharmaceutical Group, and Zhongsheng Pharmaceutical, have reached the daily limit, with the Traditional Chinese Medicine Sector overall rising, and the Traditional Chinese Medicine 50 ETF increasing by 3.21%.

cls.cnJan 6 21:42